Hypofractionation in radiotherapy for breast cancer

The Lancet

Volumn 371, Issue 9618, 2008, Pages 1050-1052

  Bartelink, Harry ^a   Arriagada, Rodrigo ^b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; HUMAN; MASTECTOMY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION DOSE HYPOFRACTIONATION;

EID: 40949148056     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60349-9     Document Type: Note

References (17)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
2. The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (2008) 10.1016/S0140-6736(08)60348-7 published online March 19.
3. The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol (2008) 10.1016/S1470-2045(08)70077-9 published online March 19.
4. Owen J., Ashton A., Bliss J., et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 7 (2006) 467-471
5. Yarnold J., Ashton A., Bliss J., et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75 (2005) 9-17
6. Regaud C. Discordance des effets des rayons X, d'une part dans la peau, d'autre part dans le testicule, par le fractionnement de la dose: diminution de l'efficacité dans la peau, maintien de l'efficacité dans le testicule. Comptes rendus hebdomadaires séances mémoires Soc biol (Paris) 97 (1927) 431-434
7. Bourhis J., Overgaard J., Audry H., et al., on behalf of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006) 843-854
8. Auquier A., Rutqvist L., Höst H., Rotstein S., and Arriagada R. Post-mastectomy megavoltage radiotherapy: the Oslo and Stockholm trials. Eur J Cancer 28 (1992) 433-437
9. Arriagada R., Rutqvist L., Mattsson A., et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 13 (1995) 2869-2878
10. Bartelink H., Horiot J., Poortmans P., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345 (2001) 1378-1387
11. Bartelink H., Horiot J., Poortmans, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25 (2007) 3259-3265
12. Romestaing P., Lehingue Y., Carrie C., et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 15 (1997) 963-968
13. Curran D., Van Dongen J., Aaronson N., et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. Eur J Cancer 34 (1998) 307-314
14. Jung H., Beck-Bornholdt H., Svoboda V., Alberti W., and Herrmann T. Quantification of late complications after radiation therapy. Radiother Oncol. 61 (2001) 233-246
15. Hooning M., Botma A., Aleman B., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99 (2007) 365-375
16. van de Vijver M., He Y., van't Veer L., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
17. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen treated node negative breast cancer. N Engl J Med 351 (2004) 2817-2826